Bristol-Myers Squibb Company BMY was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $60.90 to $64.43 in the past one month time frame.
The move came after report that the company has inked a multibillion-dollar global strategic collaboration agreement with Nektar Therapeutics.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Bristol-Myers Squibb. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Bristol-Myers Squibb currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
A better-ranked stock in the Large Cap Pharmaceuticals industry is Pfizer Inc. PFE, holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is BMY going up? Or down? Predict to see what others think:Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment